| http://www.w3.org/ns/prov#value | - Co.'s Phase 3 candidate, blisibimod, targets B-cell activating factor (BAFF), which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including systemic lupus erythematosus, Immunoglobin A nephropathy, lupus nephritis, vasculitis and others.
|
